---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-144217"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:26:23.611672+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Benitec Q3 net loss $4.4M; 9 subjects enrolled in OPMD study; on track for BB-301 dosing in 2H2023

## Summary
- Net loss of $4.4M ($0.16/shr) in Q3 2023 vs $3.3M ($0.40/shr) in Q3 2022; cash $6.6M at Mar 31, 2023.
- 9 subjects enrolled in OPMD Natural History Study in the U.S.; pace supports BB-301 dosing and interim data disclosure in 2H2023.
- R&D expenses $3.17M vs $2.17M YoY, driven by GMP manufacturing and Natural History Study; operating loss $4.4M.
- Expects FDA IND response for BB-301 in Q2 2023; Canadian site activation pending REB approval.
- CEO Jerel Banks to present at OPMD International Conference in Tel Aviv on May 16, 2023.

## SEC filing metadata
- accession: 0001193125-23-144217
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312523144217/0001193125-23-144217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312523144217/d480708d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-144217
- JSON: https://secwatch.observer/filing/0001193125-23-144217.json
- Plain text: https://secwatch.observer/filing/0001193125-23-144217.txt

## Key facts
- Earnings Releases
  Benitec Biopharma Inc. reported financial results for Third Fiscal Quarter ended March 31, 2023.
  - Period: Third Fiscal Quarter ended March 31, 2023
  - Result: reported results
  source text: On May 15, 2023 Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312523144217/0001193125-23-144217-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.